|
Dr. Cuatrecasas was President of the Pharmaceutical Research Division of Parke-Davis Co., and Corporate Vice President for Warner Lambert Company from 1989 until his retirement in 1997. From 1986 to 1989, he served as Sr. Vice President and Director of Glaxo Inc. For the prior ten years, he was Vice President of Research and Development and Director, of the Burroughs Wellcome Company.
During his career in pharmaceutical research, he was involved in the discovery, development and marketing registration of more than forty novel medicines, including: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), calsfosceril (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering).
Dr. Cuatrecasas is widely recognized for the invention and development of affinity chromatography, a process utilized within the Aethlon HemopurifierTM. He is a member of the National Academy of Sciences, The Institute of Medicine, and the American Academy of Arts & Sciences. He is a past recipient of the Wolf Prize in Medicine, the Washington University School Of Medicine Alumni Achievement Award, the Johns Hopkins University Distinguished Alumnus Award, the City of Medicine Award, and the North Carolina Governor's Medal Award in Science. Dr. Cuatrecasas has authored over 400 original publications.
| 